ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact Evaluation of a Mobile Health App to Improve Self-control and Health Outcomes of Patients With Type 2 Diabetes Mellitus (T2DM): Pilot Study "NOVAME" (NOVAME)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03663738
Recruitment Status : Active, not recruiting
First Posted : September 10, 2018
Last Update Posted : September 10, 2018
Sponsor:
Information provided by (Responsible Party):
Servicio Canario de Salud

Brief Summary:
The objective of this project is to evaluate the effectiveness and cost effectiveness of a health app (NOVAME) designed to improve the self-control of patients with T2DM and their health outcomes. The central focus of NOVAME is the continuous support to the patient and monitoring through the app that will act as a personalized and dynamic virtual coach that will help the patient to adopt healthy habits and change their behaviors through training plans in different areas: exercise physical, healthy eating, therapeutic education and emotional management The design of the evaluation is the randomized clinical trial, in the intervention arm patients will use the app NOVAME and in the control group, patients don't receive any additional educational or supporting activities beyond the usual activities provided by the Canary Islands Health Service (CIHS). The main outcome measure is the change in HbA1c at 3 months, requiring a total of 197 patients to detect a difference of at least 0.4% considering a 10% loss. As secondary measures HbA1c is collected at 12 months and other biochemical results (lipids and glucose), BMI and a series of questionnaires to measure changes in life habits (diet, physical activity), anxiety and depression, knowledge about their disease , degree of empowerment, satisfaction and usability of the app, .. Will be collected at 3 and 12 months. The differences between the arms will be measured with mixed generalized linear models. The cost effectiveness will be calculated by calculating life years adjusted for quality (QALY) and the cost of the disease, including the use of resources reported by patients. The benefits of the technology will be expressed in terms of HbA1c and QALY.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Behavioral: mobile app NOVAME Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 197 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Evaluation of the Impact of a Mobile Health App to Improve Self-control and Health Outcomes of Patients With Type 2 Diabetes Mellitus: Pilot Study "NOVAME"
Actual Study Start Date : February 5, 2018
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: health mobile app for T2DM patients
It consists of a mobile app that will be provided to patients during a period of 12 months, the patient can also continue with the usual care. The application will be synchronized with a server where all the information is recorded for further analysis. The central focus of the application consists of continuous support and monitoring through the app that has a personalized and dynamic virtual coach that will help the patient to adopt healthy habits and change their behaviors through training plans in different areas: exercise physical, healthy eating, therapeutic education and emotional management
Behavioral: mobile app NOVAME
The training program is divided into 3 periods of 21 days, where each day the patient receives a new formation pill. At the end of one of these periods there will be a week of review in which the patient will receive reminders of the contents that he has already received. These pills will help the patient to acquire healthy lifestyle habits and improve the control of the disease. The length of the program is 84 days, and once completed, the patient can repeat or intensify efforts in the areas he considers and continue to have access to the virtual coach. Patients assigned to the intervention group will receive a brief structured explanation on how to use the application and its contents.

No Intervention: Control
Receives the usual care as established in the Canary Islands Atherosclerotic Vascular Disease Prevention and Control Program (EVA)



Primary Outcome Measures :
  1. HbA1c [ Time Frame: Basal, 3 months, 12 months ]
    glycosylated hemoglobin


Secondary Outcome Measures :
  1. Total cholesterol and its fractions (LDL, HDL and nonHDL), and triglycerides [ Time Frame: Basal, 3 months, 12 months ]
    triglycerides, Total Cholesterol, LDL Cholesterol, HDL Cholesterol

  2. Glucose [ Time Frame: Basal, 3 months, 12 months ]
    glucose level

  3. BMI [ Time Frame: Basal, 3 months, 12 months ]
    Body mass index

  4. Quality of life related to health [ Time Frame: Basal, 3 months, 12 months ]
    EQ-5D-5L questionnaire



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with T2DM diagnosed at least one year prior to study enrolment
  2. 18-65 years of age
  3. Formal consent to participate in the study
  4. Regular use of mobile phone

Exclusion Criteria:

  1. Chronic kidney disease≥stage 3b, as defined by the National Kidney Foundation's Kidney Disease Outcomes and Quality Improvement Initiative (KDOQI); urinary albumin to creatinine ratio (UACR) ≥ 300 mg/g and/or urinary protein excretion ≥ 300 mg/24 hours.
  2. Acute coronary syndrome (documented angina or myocardial infarction) or stroke in the last six months or class III or IV heart failure, according to the New York Heart Association (NYHA).
  3. Proliferative diabetic retinopathy or clinically significant diabetic macular edema requiring previous treatment with retinal photocoagulation, vitrectomy, or intravitreal injections of antivascular endothelial growth factor or triamcinolone acetonide 6 months prior to study inclusion.
  4. Uncorrected severe hearing or visual impairment; or corrected visual acuity ≤ 20/40 by any cause.
  5. Diabetic foot with ulcers ≥ 2 according to Wagner scale.
  6. Liver cirrhosis
  7. Cancer unless disease free five years after diagnosis
  8. Other terminal illnesses
  9. Intellectual retardation, dementia, psychotic diseases.
  10. Active substance abuse, alcohol or drugs (must be sober for one year)
  11. Pregnancy
  12. Insufficient (Spanish) language skills
  13. Physical disability limiting participation in group education activities
  14. Concurrent participation in another clinical trial or any other investigational study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03663738


Locations
Spain
Servicio de Evaluación. Servicio Canario de Salud
Santa Cruz de Tenerife, Spain, 38004
Sponsors and Collaborators
Servicio Canario de Salud

Responsible Party: Servicio Canario de Salud
ClinicalTrials.gov Identifier: NCT03663738     History of Changes
Other Study ID Numbers: PIFUN32/17
First Posted: September 10, 2018    Key Record Dates
Last Update Posted: September 10, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases